24/10/2023
Una pastilla contra el dengue desarrollada por Johnson & Johnson ha mostrado su efectividad sobre un grupo de pacientes.
Las investigaciones relacionadas al fármaco aún están en su fase 2.
Fuente https://www.jnj.com/janssen-announces-promising-antiviral-activity-against-dengue-in-a-phase-2a-human-challenge-model?fbclid=IwAR1Kmj1_WA6Qvn_eKeETanIwVVz1B_hveaSJgpbcJUheXz3A8v5oaveY9cQ
The antiviral JNJ-1802 induced prophylactic antiviral activity against dengue in a human challenge modelDengue infects millions of people annually and could impact many more as climate change fuels outbreaksThe antiviral, previously found to be safe and well-tolerated, is now in a community-based fi...